

Luis Paz-Ares

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3328009/publications.pdf>

Version: 2024-02-01

170
papers

37,307
citations

36691

53
h-index

7836

155
g-index

176
all docs

176
docs citations

176
times ranked

30967
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Nivolumab versus Docetaxel in Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1627-1639. | 13.9 | 7,973 |
| 2 | Durvalumab after Chemoradiotherapy in Stage III Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 1919-1929. | 13.9 | 3,261 |
| 3 | Pembrolizumab plus Chemotherapy for Squamous Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2040-2051. | 13.9 | 2,676 |
| 4 | Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. <i>New England Journal of Medicine</i> , 2018, 378, 2093-2104. | 13.9 | 2,469 |
| 5 | Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. <i>New England Journal of Medicine</i> , 2018, 379, 2342-2350. | 13.9 | 2,150 |
| 6 | First-Line Nivolumab in Stage IV or Recurrent Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2415-2426. | 13.9 | 2,145 |
| 7 | Nivolumab plus Ipilimumab in Advanced Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2020-2031. | 13.9 | 1,866 |
| 8 | Durvalumab plus platinumâ€“etoposide versus platinumâ€“etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet, The</i> , 2019, 394, 1929-1939. | 6.3 | 1,274 |
| 9 | Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1â€“2 trials. <i>Lancet Oncology, The</i> , 2020, 21, 271-282. | 5.1 | 1,034 |
| 10 | First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2017, 389, 917-929. | 6.3 | 919 |
| 11 | First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 198-211. | 5.1 | 773 |
| 12 | Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and Tj ETQq0 0 OrgBT /Overclock 10 T | | |
| 13 | Current Challenges in Cancer Treatment. <i>Clinical Therapeutics</i> , 2016, 38, 1551-1566. | 1.1 | 549 |
| 14 | First-Line Nivolumab Plus Ipilimumab in Advanced Nonâ€“Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. <i>Journal of Clinical Oncology</i> , 2019, 37, 992-1000. | 0.8 | 457 |
| 15 | Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. <i>Annals of Oncology</i> , 2018, 29, i10-i19. | 0.6 | 449 |
| 16 | Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1301-1311. | 0.8 | 445 |
| 17 | Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. <i>Annals of Oncology</i> , 2017, 28, 270-277. | 0.6 | 425 |
| 18 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019, 20, 1655-1669. | 5.1 | 418 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1657-1669. | 0.5 | 395 |
| 20 | Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 51-65. | 5.1 | 356 |
| 21 | Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 288-293. | 0.5 | 328 |
| 22 | Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 860-867. | 0.5 | 323 |
| 23 | A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 730-738. | 3.2 | 265 |
| 24 | Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. <i>Lancet Oncology</i> , The, 2020, 21, 645-654. | 5.1 | 247 |
| 25 | Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. <i>Journal of Clinical Oncology</i> , 2017, 35, 412-420. | 0.8 | 237 |
| 26 | KRAS-Mutant non-small cell lung cancer: From biology to therapy. <i>Lung Cancer</i> , 2018, 124, 53-64. | 0.9 | 232 |
| 27 | Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. <i>JAMA Oncology</i> , 2015, 1, 149. | 3.4 | 224 |
| 28 | First-in-Human Dose Study of the Novel Transforming Growth Factor- β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 553-560. | 3.2 | 199 |
| 29 | Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1109-1123. | 5.1 | 193 |
| 30 | Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2008, 98, 1608-1613. | 2.9 | 155 |
| 31 | Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 165-183. | 0.5 | 134 |
| 32 | Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. <i>Annals of Oncology</i> , 2020, 31, 798-806. | 0.6 | 131 |
| 33 | Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 51-69. | 1.6 | 126 |
| 34 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1210-1222. | 0.5 | 119 |
| 35 | Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 914-947. | 0.5 | 119 |
| 36 | Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. , 2017, 5, 71. | | 113 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. <i>European Journal of Cancer</i> , 2020, 127, 160-172. | 1.3 | 112 |
| 38 | Clinicopathologic Features of Advanced Squamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1411-1422. | 0.5 | 101 |
| 39 | Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1745-1753. | 0.5 | 100 |
| 40 | Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. <i>ESMO Open</i> , 2022, 7, 100408. | 2.0 | 94 |
| 41 | Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1883-1892. | 0.5 | 93 |
| 42 | MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD. <i>European Respiratory Journal</i> , 2014, 43, 1740-1749. | 3.1 | 91 |
| 43 | First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. <i>ESMO Open</i> , 2021, 6, 100273. | 2.0 | 91 |
| 44 | Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017, 53, 79-97. | 3.4 | 80 |
| 45 | Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102978. | 2.0 | 79 |
| 46 | SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. <i>European Journal of Cancer</i> , 2020, 135, 242-250. | 1.3 | 74 |
| 47 | Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA109-LBA109. | 0.8 | 74 |
| 48 | ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. <i>Future Oncology</i> , 2019, 15, 231-239. | 1.1 | 69 |
| 49 | Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. <i>Cancer</i> , 2020, 126, 4867-4877. | 2.0 | 69 |
| 50 | Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2020, 6, 100. | 3.4 | 68 |
| 51 | MicroRNA-Dependent Regulation of Transcription in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2014, 9, e90524. | 1.1 | 65 |
| 52 | Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). <i>Annals of Oncology</i> , 2019, 30, 161-165. | 0.6 | 60 |
| 53 | Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2020, 22, 989-1003. | 1.2 | 59 |
| 54 | Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 271-280. | 0.8 | 59 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options. <i>Journal of Clinical Oncology</i> , 2022, 40, 671-680. | 0.8 | 59 |
| 56 | Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry. <i>PLoS ONE</i> , 2014, 9, e107200. | 1.1 | 58 |
| 57 | Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. <i>Clinical Lung Cancer</i> , 2018, 19, e465-e479. | 1.1 | 56 |
| 58 | <p>First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10463-10476. | 0.9 | 56 |
| 59 | Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. <i>Annals of Oncology</i> , 2019, 30, 290-296. | 0.6 | 55 |
| 60 | Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer. <i>ESMO Open</i> , 2022, 7, 100399. | 2.0 | 54 |
| 61 | FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy. <i>Journal of Thoracic Oncology</i> , 2019, 14, 641-655. | 0.5 | 50 |
| 62 | Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2019, 108, 120-128. | 1.3 | 50 |
| 63 | Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non"Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy. <i>Clinical Lung Cancer</i> , 2016, 17, 80-84. | 1.1 | 45 |
| 64 | Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). <i>Annals of Oncology</i> , 2010, 21, 195-198. | 0.6 | 41 |
| 65 | Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. <i>Lung Cancer</i> , 2017, 112, 181-187. | 0.9 | 40 |
| 66 | Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab. <i>Oncologist</i> , 2018, 23, 1092-1102. | 1.9 | 38 |
| 67 | Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2019, 20, e601-e608. | 1.1 | 38 |
| 68 | Biological therapies in nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2017, 49, 1601520. | 3.1 | 37 |
| 69 | Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. <i>Investigational New Drugs</i> , 2012, 30, 729-740. | 1.2 | 36 |
| 70 | A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. <i>Frontiers in Oncology</i> , 2020, 10, 578756. | 1.3 | 36 |
| 71 | A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non"small cell lung cancer. <i>Lung Cancer</i> , 2017, 108, 212-216. | 0.9 | 35 |
| 72 | First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light. <i>Lung Cancer</i> , 2019, 134, 245-253. | 0.9 | 35 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 289-298. | 0.5 | 35 |
| 74 | Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced <i>ALK</i> -rearranged non-small cell lung cancer. <i>European Respiratory Journal</i> , 2018, 51, 1702431. | 3.1 | 32 |
| 75 | PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN. <i>Annals of Oncology</i> , 2019, 30, v928-v929. | 0.6 | 32 |
| 76 | Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 418-425. | 1.1 | 31 |
| 77 | First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1569-1579. | 1.2 | 31 |
| 78 | Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). <i>Lung Cancer</i> , 2021, 151, 30-38. | 0.9 | 30 |
| 79 | Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. <i>Nature Medicine</i> , 2022, 28, 752-765. | 15.2 | 30 |
| 80 | Inhibiting PI3K as a therapeutic strategy against cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 572-579. | 1.2 | 28 |
| 81 | Necitumumab for the treatment of advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 705-716. | 1.1 | 28 |
| 82 | Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. <i>Lung Cancer</i> , 2020, 149, 46-52. | 0.9 | 28 |
| 83 | A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2015, 33, 8009-8009. | 0.8 | 27 |
| 84 | Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. <i>European Journal of Cancer</i> , 2014, 50, 496-505. | 1.3 | 26 |
| 85 | First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. <i>Lung Cancer</i> , 2019, 133, 10-19. | 0.9 | 25 |
| 86 | Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1701-1709. | 0.6 | 24 |
| 87 | Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. <i>Lung Cancer</i> , 2019, 134, 72-78. | 0.9 | 24 |
| 88 | Immunologic Checkpoint Blockade in Lung Cancer. <i>Seminars in Oncology</i> , 2015, 42, 402-417. | 0.8 | 23 |
| 89 | A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. <i>PLoS ONE</i> , 2019, 14, e0221994. | 1.1 | 23 |
| 90 | LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN. <i>Annals of Oncology</i> , 2020, 31, S1212-S1213. | 0.6 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5258-5271. | 3.2 | 23 |
| 92 | Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer. <i>PLoS ONE</i> , 2015, 10, e0119878. | 1.1 | 23 |
| 93 | Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 198-206. | 1.2 | 22 |
| 94 | MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320. | 1.4 | 22 |
| 95 | Durvalumab in NSCLC: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591880415. | 1.4 | 22 |
| 96 | PL02.03 Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, S844-S845. | 0.5 | 22 |
| 97 | First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions. <i>ESMO Open</i> , 2021, 6, 100003. | 2.0 | 21 |
| 98 | Safety and efficacy of AMG 655 in combination with paclitaxel and carboplatin (PC) in patients with advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2009, 27, e19048-e19048. | 0.8 | 20 |
| 99 | Lung Cancer with a High Tumor Mutational Burden. <i>New England Journal of Medicine</i> , 2018, 379, 1093-1094. | 13.9 | 18 |
| 100 | Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study. <i>Lung Cancer</i> , 2022, 167, 41-48. | 0.9 | 18 |
| 101 | Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain. <i>ESMO Open</i> , 2020, 5, e000828. | 2.0 | 17 |
| 102 | Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. <i>ESMO Open</i> , 2021, 6, 100113. | 2.0 | 17 |
| 103 | Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. <i>Clinical Lung Cancer</i> , 2018, 19, 331-339. | 1.1 | 15 |
| 104 | FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. <i>EBioMedicine</i> , 2020, 53, 102683. | 2.7 | 15 |
| 105 | SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). <i>Clinical and Translational Oncology</i> , 2009, 11, 284-289. | 1.2 | 14 |
| 106 | Reflexiones sobre la implementación del cribado mediante tomografía computarizada de baja dosis en personas con riesgo elevado de padecer cáncer de pulmón en España. <i>Archivos De Bronconeumología</i> , 2017, 53, 568-573. | 0.4 | 14 |
| 107 | Phase II Study of Trabectedin in Pretreated Patients with Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2007, 6, 522-528. | 1.0 | 13 |
| 108 | Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement. <i>Clinical Lung Cancer</i> , 2017, 18, 667-674.e1. | 1.1 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR -Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. <i>Clinical Lung Cancer</i> , 2018, 19, 213-220.e4. | 1.1 | 13 |
| 110 | Lurbinectedin in the treatment of relapsed small cell lung cancer. <i>Future Oncology</i> , 2021, 17, 2279-2289. | 1.1 | 13 |
| 111 | Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous Non-Small-Cell Lung Cancer in KEYNOTE-407. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100225. | 0.6 | 13 |
| 112 | Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2015, 33, LBA109-LBA109. | 0.8 | 13 |
| 113 | First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2021, 9, A486-A487. | | 13 |
| 114 | FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective. <i>Lung Cancer</i> , 2019, 131, 112-121. | 0.9 | 12 |
| 115 | Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. <i>Clinical Lung Cancer</i> , 2019, 20, e407-e412. | 1.1 | 12 |
| 116 | A phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC). <i>Journal of Clinical Oncology</i> , 2004, 22, 3543-3543. | 0.8 | 12 |
| 117 | Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib. <i>Frontiers in Medicine</i> , 2017, 4, 36. | 1.2 | 11 |
| 118 | Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. <i>JCO Precision Oncology</i> , 2019, 3, 1-13. | 1.5 | 11 |
| 119 | Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. <i>Clinical and Translational Oncology</i> , 2020, 22, 759-771. | 1.2 | 11 |
| 120 | Abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227. <i>Cancer Research</i> , 2018, 78, CT077-CT077. | 0.4 | 11 |
| 121 | 30 Immunotherapy in advanced NSCLC: from the tsunami of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). <i>ESMO Open</i> , 2018, 3, e000298. | 2.0 | 10 |
| 122 | Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. <i>Future Oncology</i> , 2019, 15, 1363-1383. | 1.1 | 10 |
| 123 | Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial. <i>ESMO Open</i> , 2022, 7, 100410. | 2.0 | 10 |
| 124 | Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments. <i>Clinical Lung Cancer</i> , 2018, 19, 65-73.e7. | 1.1 | 9 |
| 125 | First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1073-1082. | 1.0 | 9 |
| 126 | Incidence of venous thromboembolism in patients with non-hematological cancer admitted for COVID-19 at a third-level hospital in Madrid. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 471-478. | 1.0 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | MA16.06 Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN. <i>Journal of Thoracic Oncology</i> , 2021, 16, S939. | 0.5 | 8 |
| 128 | Treatment for early-stage lung cancer: what next?. <i>Lancet, The</i> , 2014, 383, 1528-1530. | 6.3 | 7 |
| 129 | Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2018, 19, 301-314. | 1.1 | 7 |
| 130 | The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 233-242. | 1.0 | 7 |
| 131 | Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20522-e20522. | 0.8 | 7 |
| 132 | Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?. <i>Translational Lung Cancer Research</i> , 2016, 5, 95-7. | 1.3 | 7 |
| 133 | Lung Cancer and Microbiome. <i>Archivos De Bronconeumologia</i> , 2020, 56, 3-4. | 0.4 | 6 |
| 134 | OA11.04 Lurbinectedin With Irinotecan in Relapsed Small Cell Lung Cancer. Results From the Expansion Stage of a Phase I-II Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, S127. | 0.5 | 6 |
| 135 | A phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC). <i>Journal of Clinical Oncology</i> , 2004, 22, 3543-3543. | 0.8 | 6 |
| 136 | Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8055-8055. | 0.8 | 6 |
| 137 | RESILIENT part 1: A phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer. <i>Cancer</i> , 2022, , . | 2.0 | 5 |
| 138 | Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer. <i>Medical Oncology</i> , 2016, 33, 105. | 1.2 | 3 |
| 139 | Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy. <i>Clinical and Translational Oncology</i> , 2017, 19, 219-226. | 1.2 | 3 |
| 140 | Phase II study of irinotecan (cpt-11) and cisplatin (cddp) regimen (IP) with concurrent thoracic radiotherapy (TRT) in limited-stage small cell lung cancer (LS-SCLC). <i>Journal of Clinical Oncology</i> , 2006, 24, 7084-7084. | 0.8 | 3 |
| 141 | Multiaim, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8120-TPS8120. | 0.8 | 3 |
| 142 | Tunable gold nanorod/NAO conjugates for selective drug delivery in mitochondria-targeted cancer therapy. <i>Nanoscale</i> , 2022, 14, 8028-8040. | 2.8 | 3 |
| 143 | Osimertinib in EGFR -mutant NSCLC: how to select patients and when to treat. <i>Lancet Oncology, The</i> , 2016, 17, 1622-1623. | 5.1 | 2 |
| 144 | Foreword to "The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms". <i>British Journal of Cancer</i> , 2020, 123, 1-2. | 2.9 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|--------|-----------|
| 145 | Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. <i>Future Oncology</i> , 2021, 17, 1165-1184. | 1.1 | 2 |
| 146 | Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8524-8524. | 0.8 | 2 |
| 147 | Inmunoterapia en el c ncer: grandes expectativas en el mundo de la oncolog a, pero un motivo de preocupaci n renal. <i>Nefrolog a</i> , 2019, 39, 94-96. | 0.2 | 1 |
| 148 | Combination treatment options for small-cell lung cancer    Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e84. | 5.1 | 1 |
| 149 | Abstract CT154: Isatuximab (Isa) plus atezolizumab (Atezo) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label multicenter study. , 2021, , . | | 1 |
| 150 | A phase Ib study of abemaciclib in combination with multiple single agents in stage IV NSCLC.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8047-8047. | 0.8 | 1 |
| 151 | Safety and efficacy of necitumumab continuation therapy: Subgroup analysis of phase 3 SQUIRE study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19024-e19024. | 0.8 | 1 |
| 152 | A phase II multicenter, randomized, placebo-controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9107-TPS9107. | 0.8 | 1 |
| 153 | Between Bench and Bed Side: PI3K Inhibitors. <i>Current Molecular Pharmacology</i> , 2010, 3, 79-90. | 0.7 | 1 |
| 154 | Clinical activity and cardiac tolerability of metronomic non-pegylated liposomal doxorubicin in heavily pre-treated patients with metastatic breast cancer: A single institucion experience.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11570-e11570. | 0.8 | 1 |
| 155 | P37  ...Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-   and PD-L1, in cervical cancer. , 2019, , . | | 1 |
| 156 | Entrectinib in neurotrophic receptor tyrosine kinase fusion-positive (NTRK- fp) non-small cell lung cancer (NSCLC): integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. <i>Pneumologie</i> , 2020, 74, . | 0.1 | 1 |
| 157 | Summary of   The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms  . <i>British Journal of Cancer</i> , 2020, 123, 36-36. | 2.9 | 0 |
| 158 | Response to: Bintrafusp Alfa in Second-Line Treatment of Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, e24. | 0.5 | 0 |
| 159 | Procalcitonin (PCT) as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. <i>Journal of Clinical Oncology</i> , 2004, 22, 8037-8037. | 0.8 | 0 |
| 160 | GAIN-(L): Efficacy and biomarker findings of RG7160 (GA201), a novel, dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with first-line cisplatin and pemetrexed in metastatic nonsquamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7544-7544. | 0.8 | 0 |
| 161 | Circulating tumor cells (CTCs) in patients with HER2-negative recurrent or metastatic breast cancer treated with eribulin as third-line therapy: ONSITE trial (OncoSur Analysis of the Treatment in Third) Tj ETQq1 1 0.7848 14 rgBT /Overlo | 0.7848 | 14 |
| 162 | pERK as a new prognostic factor in resected, early-staged, non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e18501-e18501. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | CheckMate 817: Safety of flat-dose nivolumab (nivo) plus weight-based ipilimumab (ipi) for the first line (100%) treatment of advanced non-small cell lung cancer (NSCLC). <i>Pneumologie</i> , 2019, 73, . | 0.1 | 0 |
| 164 | CASPIAN: OS results from a randomised Phase III study of first-line Durvalumab ± Tremelimumab plus chemotherapy in ED-SCLC: OS-Ergebnisse von CASPIAN, einer randomisierten Phase-III-Studie zur Erstlinientherapie von Durvalumab ± Tremelimumab + Chemotherapie beim Extensive Stage kleinzelligen Lungenkarzinom (ES-SCLC). , 2020, 74, . | | 0 |
| 165 | Envolving treatment of fever and neutropenia in cancer patients. , 2002, 4, 297-307. | | 0 |
| 166 | Procalcitonin (PCT) as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. <i>Journal of Clinical Oncology</i> , 2004, 22, 8037-8037. | 0.8 | 0 |
| 167 | Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTALung platform. <i>Scientific Reports</i> , 2022, 12, 8342. | 1.6 | 0 |
| 168 | Abstract 1245: Comprehensive analysis of non-small cell lung cancer identifies molecular genotype-immunophenotype associations and candidate biomarkers predictive of response to immunotherapy. <i>Cancer Research</i> , 2022, 82, 1245-1245. | 0.4 | 0 |
| 169 | Abstract 3101: Evaluation of novel therapeutic strategies for KRAS mutated NSCLC patients using our own collections of PDX and PDX-derived organoids. <i>Cancer Research</i> , 2022, 82, 3101-3101. | 0.4 | 0 |
| 170 | Abstract 414: Comprehensive molecular characterization of mechanisms involved in primary resistance to EGFR tyrosine kinase inhibitors. <i>Cancer Research</i> , 2022, 82, 414-414. | 0.4 | 0 |